Skip to main content

Advertisement

Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Association between in vivo bone formation and ex vivo migratory capacity of human bone marrow stromal cells

Fig. 4

PDGF selectively enhanced the migration of hBMSC-TERT+Bone versus hBMSC-TERT–Bone. a Transwell migration ability of hBMSC-TERT+Bone versus hBMSC-TERT–Bone toward the chemoattractants including: IGF-1 (10 ng/ml), SDF-1 (100 ng/ml), PDGF-BB (100 ng/ml), and TNFα (10 ng/ml). Photomicrographs represent images of the migrated cells for each condition. b Transwell migration assay of hBMSC-TERT+Bone and hBMSC-TERT–Bone cells toward different subtypes of PDGF recombinant protein (100 ng/ml). PDGF isoforms have applied either in the lower chamber (PDGF-AA, PDGF-AB, PDGF-BB) of the transwell migration assay to examine the migratory capacity of the cells or applied to both lower and upper chambers of the assay (PDGF-AA + PDGF-AA, PDGF-AB + PDGF-Ab, PDGF-BB + PDGF-BB) to inhibit the migration. c Dose-dependent effect of PDGF-BB (10, 50, or 100 ng/ml) on the transwell migration of hBMSC-TERT+Bone or hBMSC-TERT–Bone cells. d Dose-dependent effect of SU-16f inhibitor (a selective inhibitor for PDGFRβ) on the transwell migration of hBMSC-TERT+Bone or hBMSC-TERT–Bone cells. Data presented as mean ± SEM of at least three independent experiments (*p ≤0.05, **p ≤0.01, ***p ≤0.005, ****p ≤0.001, as compared with control). DMSO dimethyl sulfoxide, hBMSC human bone marrow stromal stem cells, IGF1 insulin-like growth factor 1, PDGF platelet-derived growth factor, SDF1stromal cell-derived factor 1, TNFα tumor necrosis factor alpha

Back to article page